Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) EBT Margin: 2020-2024

Historic EBT Margin for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2024 value amounting to 69.26%.

  • Fulcrum Therapeutics' EBT Margin rose 277187.00% to 69.26% in Q2 2024 from the same period last year, while for Jun 2024 it was -24.52%, marking a year-over-year increase of 321028.00%. This contributed to the annual value of -12.16% for FY2024, which is 345790.00% up from last year.
  • Fulcrum Therapeutics' EBT Margin amounted to 69.26% in Q2 2024, which was up 102.44% from -2,842.25% recorded in Q4 2023.
  • In the past 5 years, Fulcrum Therapeutics' EBT Margin ranged from a high of 69.26% in Q2 2024 and a low of -8,399.66% during Q1 2023.
  • Moreover, its 3-year median value for EBT Margin was -2,702.61% (2023), whereas its average is -2,852.46%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by 739,935bps in 2023, then soared by 277,187bps in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' EBT Margin (Quarterly) stood at -419.41% in 2020, then slumped by 4,489bps to -464.29% in 2021, then plummeted by 335,103bps to -3,815.33% in 2022, then surged by 97,308bps to -2,842.25% in 2023, then soared by 277,187bps to 69.26% in 2024.
  • Its last three reported values are 69.26% in Q2 2024, -2,842.25% for Q4 2023, and -3,164.30% during Q3 2023.